Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer
Matthew Fankhauser, Yuen Tan, Geoff Macintyre, Izhak Haviv, Matthew KH Hong, Anne Nguyen, John S Pedersen, Anthony J Costello, Christopher M Hovens, Niall M Corcoran
CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2014
PURPOSE: It has been recognized for almost a decade that concentrations of signaling androgens sufficient to activate the androgen receptor are present in castration-resistant prostate cancer tissue. The source of these androgens is highly controversial, with three competing models proposed. We, therefore, wished to determine the androgenic potential of human benign and malignant (hormone-naïve and treated) prostate tissue when incubated with various precursors and examine concomitant changes in enzyme expression. EXPERIMENTAL DESIGN: Freshly harvested prostate tissue [benign, hormone-naïve, and hormone-refractory prostate cancer (HRPC)] was incubated in excess concentrations of cholesterol,..View full abstract
Awarded by NHMRC grant
This work is supported by NHMRC grant 102408 (to N.M. Corcoran, J.S. Pedersen, A.J. Costello, and C.M. Hovens). N.M. Corcoran is supported by a David Bickart Clinician Research Fellowship from the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne. G. Macintyre is supported by NICTA. NICTA is funded by the Australian Government as represented by the Department of Broadband, Communications and the Digital Economy and the Australian Research Council through the ICT Centre of Excellence program.